A Survey of Maribavir Tablets in Participants With Cytomegalovirus Infection

Condition(s) studied

Investigational drug(s) / intervention(s)

Maribavir: Maribavir tablets

Study summary

This study is a survey in Japan of Maribavir tablets used to treat participants with Cytomegalovirus (CMV) infection refractory to existing anti-CMV therapy in organ transplantation (including hematopoietic stem cell transplantation).

The main aim of the study is to check if treatment with Maribavir can protect Japanese people against CMV infection, and to check side effect from the study treatment. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study.

During the study, participants with CMV infection will take Maribavir tablets according to their clinic's standard practice. The study doctors will check for side effects from Maribavir tablets for 27 weeks.

Eligibility

Primary outcome measure(s)

• Number of Participants who Experience at Least One Adverse Drug Reactions (ADRs) — Up to 27 weeks
  An adverse event (AE) is any untoward or undesirable medical occurrence in a participant linked in time with the use of a pharmaceutical/ medicinal product. They are not limited to the events with clear causal relationship with treatment with concerned drug. Adverse drug reaction refers (ADR) to AE related to administered drug.

Trial sites (1)

More Takeda trials in Japan

Other trials for the same condition